Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Ambarella Inc (AMBA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Ambarella Inc — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $224 (market cap $29.60B), while Ambarella Inc trades at $83.53 (market cap $3.64B). The key difference: Alnylam Pharmaceuticals, Inc. is far larger — about 8.1× Ambarella Inc's market cap, and Ambarella Inc is trading nearer its 52-week high, Alnylam Pharmaceuticals, Inc. nearer its low. Which is the better fit depends on your goals.
| ALNY | AMBA | |
|---|---|---|
Market Cap | $29.60B | $3.64B |
Sector | Health | Technology |
52-Week High | $491.22 | $95.51 |
52-Week Low | $205.48 | $48.65 |
Enterprise Value | $27.56B | $3.37B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $223.43, up 2.97% in 24 hours, with a bearish technical signal despite recent gains. The stock shows strong profitability with a 79.65% gross margin and 96.55% ROE, but valuation ratios like P/E of 38.54 are elevated. Recent Q2 2026 earnings missed estimates, and multiple law firms are investigating potential securities fraud, adding uncertainty.
Outlook is mixed: analyst consensus is bullish with a $370.07 price target, but risks include ongoing fraud probes and earnings volatility. Revenue growth is robust, projected to reach $4.8B in 2026, yet investors face headwinds from legal issues and technical bearishness.
Ambarella (AMBA) trades at $83.53, up 1.82% with bullish technical signals and strong analyst support. The company shows improving revenue trends ($405M projected for 2026) and consistent earnings beats, though profitability remains negative. Recent news highlights potential acquisition interest from NXP Semiconductors and strong positioning in edge AI markets.
Outlook remains positive with 58% analyst buy ratings and $108.67 price target, representing 30% upside. Key risks include ongoing net losses, competitive pressures in semiconductor space, and execution challenges in AI chip adoption. The stock offers growth exposure to physical AI trend but requires patience for profitability turnaround.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Ambarella Inc
Ambarella is a semiconductor company specializing in low-power video compression and computer vision processors. Its chips power AI cameras for security, automotive safety, and robotics applications.
Read more on AMBA →
